Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stomach Neoplasms | 37 | 2024 | 2339 | 3.890 |
Why?
|
| Adenocarcinoma | 42 | 2024 | 7920 | 3.000 |
Why?
|
| Esophageal Neoplasms | 35 | 2024 | 3241 | 2.830 |
Why?
|
| Gastrectomy | 9 | 2024 | 476 | 1.900 |
Why?
|
| Esophagogastric Junction | 12 | 2024 | 558 | 1.750 |
Why?
|
| Chemoradiotherapy | 21 | 2024 | 2038 | 1.190 |
Why?
|
| Chemoradiotherapy, Adjuvant | 9 | 2022 | 561 | 1.000 |
Why?
|
| Carcinoma, Squamous Cell | 10 | 2022 | 5605 | 1.000 |
Why?
|
| Esophagectomy | 10 | 2021 | 946 | 0.870 |
Why?
|
| Neoadjuvant Therapy | 16 | 2024 | 5246 | 0.820 |
Why?
|
| Peritoneal Neoplasms | 6 | 2024 | 866 | 0.800 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2022 | 4007 | 0.690 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 19 | 2024 | 16750 | 0.670 |
Why?
|
| Hyperthermia, Induced | 2 | 2024 | 514 | 0.660 |
Why?
|
| Geriatric Assessment | 1 | 2015 | 288 | 0.450 |
Why?
|
| Fluorouracil | 6 | 2020 | 1990 | 0.420 |
Why?
|
| Combined Modality Therapy | 14 | 2024 | 9054 | 0.420 |
Why?
|
| Oxonic Acid | 1 | 2011 | 24 | 0.380 |
Why?
|
| Tegafur | 1 | 2011 | 51 | 0.380 |
Why?
|
| Lymph Node Excision | 3 | 2024 | 2068 | 0.380 |
Why?
|
| Neoplasm Staging | 15 | 2021 | 14037 | 0.380 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2017 | 1347 | 0.330 |
Why?
|
| Receptor, ErbB-2 | 3 | 2024 | 2658 | 0.330 |
Why?
|
| Aged | 36 | 2024 | 73601 | 0.310 |
Why?
|
| Survival Rate | 13 | 2024 | 12528 | 0.310 |
Why?
|
| Middle Aged | 40 | 2024 | 90517 | 0.300 |
Why?
|
| Humans | 66 | 2024 | 270709 | 0.300 |
Why?
|
| Prognosis | 20 | 2024 | 22528 | 0.300 |
Why?
|
| Induction Chemotherapy | 3 | 2024 | 680 | 0.300 |
Why?
|
| Follow-Up Studies | 14 | 2024 | 15274 | 0.290 |
Why?
|
| Aged, 80 and over | 22 | 2024 | 31113 | 0.290 |
Why?
|
| Paclitaxel | 3 | 2020 | 2114 | 0.270 |
Why?
|
| Camptothecin | 2 | 2020 | 540 | 0.260 |
Why?
|
| Male | 40 | 2024 | 128479 | 0.250 |
Why?
|
| Adult | 29 | 2024 | 82042 | 0.250 |
Why?
|
| Antibodies, Monoclonal | 6 | 2022 | 4470 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2023 | 10409 | 0.240 |
Why?
|
| Preoperative Care | 2 | 2021 | 1581 | 0.230 |
Why?
|
| Antineoplastic Agents | 8 | 2022 | 14639 | 0.230 |
Why?
|
| Female | 40 | 2024 | 148873 | 0.230 |
Why?
|
| Capecitabine | 2 | 2017 | 391 | 0.220 |
Why?
|
| Trastuzumab | 3 | 2017 | 743 | 0.210 |
Why?
|
| Treatment Outcome | 15 | 2020 | 33847 | 0.210 |
Why?
|
| Perfusion | 2 | 2024 | 281 | 0.210 |
Why?
|
| Biomarkers, Tumor | 4 | 2024 | 10728 | 0.210 |
Why?
|
| Esophagoscopy | 2 | 2012 | 310 | 0.210 |
Why?
|
| Prospective Studies | 10 | 2024 | 13407 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2019 | 3429 | 0.200 |
Why?
|
| Retrospective Studies | 25 | 2024 | 39968 | 0.200 |
Why?
|
| Cisplatin | 3 | 2020 | 2509 | 0.200 |
Why?
|
| Disease-Free Survival | 10 | 2020 | 10268 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2020 | 6255 | 0.180 |
Why?
|
| B7-H1 Antigen | 2 | 2024 | 1098 | 0.180 |
Why?
|
| Perineum | 1 | 2021 | 115 | 0.180 |
Why?
|
| Salvage Therapy | 5 | 2017 | 2124 | 0.170 |
Why?
|
| Lymph Nodes | 2 | 2021 | 3081 | 0.170 |
Why?
|
| Positron-Emission Tomography | 5 | 2015 | 2199 | 0.170 |
Why?
|
| Phenotype | 1 | 2011 | 6503 | 0.170 |
Why?
|
| Nomograms | 2 | 2012 | 312 | 0.170 |
Why?
|
| Platinum Compounds | 2 | 2017 | 129 | 0.170 |
Why?
|
| Ipilimumab | 1 | 2024 | 772 | 0.160 |
Why?
|
| Patient Selection | 2 | 2017 | 2029 | 0.160 |
Why?
|
| Mitomycin | 1 | 2020 | 216 | 0.160 |
Why?
|
| Taxoids | 3 | 2017 | 1019 | 0.150 |
Why?
|
| Proportional Hazards Models | 5 | 2022 | 5093 | 0.150 |
Why?
|
| Remission Induction | 4 | 2017 | 3658 | 0.140 |
Why?
|
| Barrett Esophagus | 2 | 2018 | 560 | 0.140 |
Why?
|
| Neovascularization, Pathologic | 2 | 2014 | 1587 | 0.140 |
Why?
|
| Cancer Care Facilities | 2 | 2020 | 907 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 1404 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2014 | 266 | 0.120 |
Why?
|
| Treatment Refusal | 2 | 2013 | 127 | 0.120 |
Why?
|
| Bayes Theorem | 1 | 2020 | 1061 | 0.120 |
Why?
|
| Organoplatinum Compounds | 2 | 2015 | 707 | 0.120 |
Why?
|
| Endoscopy | 1 | 2018 | 495 | 0.120 |
Why?
|
| Esophagus | 1 | 2018 | 562 | 0.120 |
Why?
|
| Linear Models | 1 | 2017 | 1092 | 0.120 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 881 | 0.120 |
Why?
|
| Texas | 3 | 2020 | 6445 | 0.110 |
Why?
|
| Lymphatic Metastasis | 4 | 2021 | 4969 | 0.110 |
Why?
|
| Neoplasm Grading | 2 | 2015 | 1828 | 0.110 |
Why?
|
| Risk Factors | 5 | 2015 | 17850 | 0.100 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2013 | 503 | 0.100 |
Why?
|
| Carcinoma | 1 | 2024 | 2610 | 0.100 |
Why?
|
| Clinical Trials as Topic | 3 | 2017 | 3840 | 0.100 |
Why?
|
| Confidence Intervals | 1 | 2012 | 747 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 3 | 2019 | 2396 | 0.090 |
Why?
|
| Cancer Survivors | 1 | 2017 | 746 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 1270 | 0.080 |
Why?
|
| Young Adult | 7 | 2021 | 22241 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 5332 | 0.080 |
Why?
|
| Survival Analysis | 6 | 2020 | 9278 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2011 | 632 | 0.080 |
Why?
|
| DNA Copy Number Variations | 3 | 2021 | 1576 | 0.080 |
Why?
|
| Brain Neoplasms | 2 | 2017 | 4971 | 0.080 |
Why?
|
| Time Factors | 3 | 2020 | 12974 | 0.070 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2013 | 742 | 0.070 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 4315 | 0.070 |
Why?
|
| Disease Management | 1 | 2013 | 1092 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 4964 | 0.070 |
Why?
|
| Treatment Failure | 3 | 2014 | 1429 | 0.070 |
Why?
|
| Hospitalization | 1 | 2015 | 2169 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 12041 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2021 | 9451 | 0.060 |
Why?
|
| Deoxycytidine | 1 | 2011 | 1389 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5582 | 0.060 |
Why?
|
| Genes, erbB | 1 | 2023 | 27 | 0.050 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2022 | 78 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2024 | 627 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 4054 | 0.050 |
Why?
|
| Preoperative Period | 2 | 2013 | 348 | 0.050 |
Why?
|
| Microsatellite Instability | 1 | 2024 | 414 | 0.050 |
Why?
|
| Neoplasms | 2 | 2023 | 15951 | 0.050 |
Why?
|
| Nausea | 1 | 2023 | 537 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2023 | 315 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 381 | 0.050 |
Why?
|
| Early Detection of Cancer | 2 | 2013 | 1345 | 0.040 |
Why?
|
| ErbB Receptors | 2 | 2023 | 2376 | 0.040 |
Why?
|
| Logistic Models | 2 | 2020 | 3423 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2020 | 2259 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2024 | 521 | 0.040 |
Why?
|
| Diarrhea | 1 | 2023 | 722 | 0.040 |
Why?
|
| Leucovorin | 1 | 2020 | 345 | 0.040 |
Why?
|
| Ploidies | 1 | 2019 | 250 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2020 | 983 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2020 | 6765 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 228 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 5145 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 249 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2021 | 698 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2021 | 675 | 0.040 |
Why?
|
| Glycolysis | 1 | 2020 | 529 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2022 | 1044 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 674 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 4842 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2013 | 1580 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 561 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 9048 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 273 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2020 | 2033 | 0.030 |
Why?
|
| Disease Progression | 2 | 2018 | 6880 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2013 | 2657 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2019 | 1958 | 0.030 |
Why?
|
| Bridged-Ring Compounds | 1 | 2013 | 194 | 0.030 |
Why?
|
| Drug Approval | 1 | 2014 | 173 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2014 | 734 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2021 | 2157 | 0.030 |
Why?
|
| Gastroscopy | 1 | 2012 | 156 | 0.030 |
Why?
|
| Adolescent | 1 | 2012 | 32691 | 0.020 |
Why?
|
| Mutation | 2 | 2023 | 15922 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2013 | 666 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 5053 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2011 | 205 | 0.020 |
Why?
|
| Decision Making | 1 | 2017 | 1249 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 426 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2013 | 551 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 965 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 16243 | 0.020 |
Why?
|
| Cetuximab | 1 | 2011 | 474 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 481 | 0.020 |
Why?
|
| Reoperation | 1 | 2013 | 1388 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 1998 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2023 | 4965 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 3058 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2012 | 2272 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2013 | 1858 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 3490 | 0.010 |
Why?
|
| Prevalence | 1 | 2012 | 3392 | 0.010 |
Why?
|
| Research Design | 1 | 2011 | 1559 | 0.010 |
Why?
|
| United States | 1 | 2021 | 15817 | 0.010 |
Why?
|
| Incidence | 1 | 2013 | 5814 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2011 | 1464 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 5417 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 12035 | 0.010 |
Why?
|